Dbv technologies reports first quarter 2024 financial results and business update

Montrouge, france, may 7, 2024 dbv technologies reports first quarter 2024 financial results and business update vitesse enrollment on track to screen last patient by q3 2024 appointment of robert pietrusko, pharmd to chief regulatory officer q1 2024 closes with a cash balance of $101.5 million dbv technologies (euronext: dbv – isin: fr0010417345 – nasdaq stock market: dbvt), a clinical-stage biopharmaceutical company focused on treatment options for food allergies and other immunologic conditions with significant unmet medical need, today reported financial results for the first quarter 2024. the quarterly financial statements were approved by the board of directors on may 7, 2024.
DBVT Ratings Summary
DBVT Quant Ranking